

**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES**  
**May 13, 2014**

The meeting was called to order at approximately 1:39 p.m. on Tuesday, May 13, 2014.

Committee members present: Melissa Bowlby, PA-C; Anita Steinbergh, D.O.; James Fry, PA-C; Sean Stiltner, D.O.; Margaret Huwer, Pharm.D.; and Theresa Ash, Pharm.D;

Staff members present: Sallie Debolt, and Cathy Hacker

***I. Review of the April 8, 2014 minutes:***

Mr. Fry moved to approve the minutes from the May 13, 2014 meeting. Dr. Steinbergh seconded the motion. All members voted aye. The motion carried.

***II. Formulary Review:***

Ms. Debolt began the meeting by informing the committee that Naloxone is properly listed on the physician assistant formulary in the CTP may prescribe category for resuscitation of narcotic overdose and that no changes to the formulary are needed at this time.

Ms. Debolt agreed to prepare a guidance document for physician assistant(s) prescribing schedule II medications.

Mr. Fry joined the meeting.

Ms. Huwer requested that the naloxone language from chapter 4730 rule be added to the formulary to better clarify.

Dr. Steinbergh moved to approve the naloxone language in the formulary. Dr. Stiltner seconded the motion. All members voted aye. The motion carried.

Ms. Debolt distributed a handout from a mail order pharmacy that asked if a CTP holder initially prescribes a 7 day supply of a schedule II analgesic if the provider could write the subsequent prescription for a 30 day supply.

Dr. Stiltner stated that a 30 day supply of this medication is the maximum number of pills that can be written on their own. The law states that they cannot write for more than 7 days for the initial prescription. If the physician has written the initial prescription then the PA can refill for a 30 day supply. If the PA writes the first prescription for the 7 day supply then the physician needs to see and evaluate the patient and agree that a 30 day supply is needed prior to the PA prescribing the second round. Ms. Huwer stated that this would cause the pharmacist to look at the original prescription to see who wrote for the initial dose or they could utilize the OARRS system.

Ms. Bowlby asked if the committee could discuss mucolytic agents such as Mucomist under that are currently under the CTP may not prescribe. She stated that the OAPA had requested the review. Ms. Debolt stated that since it was not on the

agenda it needs to be brought back to the committee at its next meeting to give the committee time to review the request.

**III.** The committee then discussed the special services plans from Vein Care Center that is requesting approval for the following procedures: Sclerotherapy:

The committee agreed that this application was in keeping with the other applications that had been previously approved for Sclerotherapy.

Dr. Steinbergh requested that they remove the name of a specific PA.

Dr. Stiltner moved to approve this application provided that they remove the name of the specific PA. Mr. Fry seconded the motion. All members voted aye. The motion carried.

The committee then discussed the special services plans from Vein Care Center that is requesting approval for the following procedures: ambulatory Plebectomy:

The committee felt that this is a very complicated and invasive procedure and had many concerns regarding patient safety. They felt that this requires the expertise of a physician to perform.

Dr. Steinbergh recommended that this application be forwarded to the Boards PA committee for their comments. Mr. Fry seconded the motion all members voted aye. The motion carried.

**IV. *Review changes to the model orthopaedic plan:***

Ms. Debolt stated that the model supervisory plan was the result of the PA association working along with the Orthopaedic association and the Board to develop this application in an attempt to have certain routine injections that would no longer need to come to the PAPC or the PA committee for approval provided that the supervising physician agree to the terms of this model supervisory plan for orthopaedic injections. She further stated that the last revision was to remove the onsite and offsite requirement and instead added that the supervising physician is to develop the treatment plan and following the development of the treatment plan, the PA can give the injections. The physician would be responsible for reviewing the records and is the person to sign off when the treatment plan has been completed.

Dr. Steinbergh moved to approve this application. Dr. Stiltner seconded the motion all members voted aye. The motion carried.

**V. *Review changes to the rules:***

Ms. Debolt explained to the committee that there was a need to remove throughout the rules the reference to "on a form prescribed by the Board." She stated that this language requires that JCARR review and approve our applications. She is recommending that the language be changed to read "shall file a written application in the manner provided by the particular section of the Revised Code that authorizes the application.

Dr. Steinbergh moved to approve this change. Dr. Stiltner seconded the motion. All members voted aye. The motion carried.

**VI. *New business matters:***

No new business matters were discussed.

The Physician Assistant Policy Committee meeting was adjourned by Ms. Bowlby at approximately 2:29 p.m. on Tuesday, May 13, 2014.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on May 13, 2014.

---

James Fry, PA-C,  
Chair, PAPC

Copies of documents and/or materials referenced in the minutes of the Physician Assistant Policy Committee meeting are available at the Board offices.